Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.4.0.3
Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Revenues $ 0 $ 0 $ 0 $ 0
Operating expenses:        
General and administrative expenses 868,433 853,177 1,733,946 1,723,533
Research and development expenses 386,285 402,495 800,288 802,230
Total operating expenses 1,254,718 1,255,672 2,534,234 2,525,763
Operating loss (1,254,718) (1,255,672) (2,534,234) (2,525,763)
Other income (expense):        
Interest expense (66,823) (50,556) (210,569) (78,320)
Gain on exercise of warrants and conversion of debt 13,503 0 142,964 224,000
Loss on warrant derivative modification 0 (624,016) 0 (1,924,186)
Decrease to fair value of derivative 54,982 1,096,278 192,128 3,849,448
Total other income 1,662 421,706 124,523 2,070,942
Net loss $ (1,253,056) $ (833,966) $ (2,409,711) $ (454,821)
Earnings per share - basic and diluted        
Net loss per common share - basic and diluted $ (0.01) $ (0.01) $ (0.02) $ (0.01)
Weighted common shares - basic and diluted 109,524,010 76,076,487 109,069,824 74,716,734